Targeted Oncology
Targeted Oncology
Targeted Oncology

Specialties

Results of the ZUMA-1 Trial Exploring KTE-C19 in NHL

Sattva S. Neelapu, MD
Published Online:11:28 AM, Fri May 19, 2017

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.
Publications